Correction of a pathogenic gene mutation in human embryos
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [112]
In the citing paper
“Of the studies that have been conducted, the reported efficiencies of repair with templates in human embryos are very low (5,7,8).”
From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)”
Cited work 10.1126/science.1248024 · retracted 2025-01-09 · notice 10.1126/science.adv1263 · this paper published 2017-08
Citations
Cites
1 retracted
Mitosis Inhibits DNA Double-Strand Break Repair to Guard Against Telomere Fusions
Orthwein, A., Fradet-Turcotte, A., Noordermeer, S. M., Canny, M. D., Brun, C. M., Strecker, J., Escribano-Diaz, C., & Durocher, D. (2014) · Science · doi:10.1126/science.1248024 · Cited by 319
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
Items 101–200 of 948
Piergentili, R., Rio, A. D., Signore, F., Ronchi, F. U., Marinelli, E., & Zaami, S. (2021) · Cells · doi:10.3390/cells10050969 · Cited by 109
“The efficiency of both approaches heavily depend on the number of somatic cells that can be edited, thus the idea of manipulating the zygote or the embryo at a very early stage, being much lower the number of cells to be targeted, or to act on gametes to significantly reduce mosaicism [63].”
BackgroundMethodInfluentialEfficient embryonic homozygous gene conversion via RAD51-enhanced interhomolog repair
Wilde, J. J., Aida, T., del Rosario, R. C. H., Kaiser, T., Qi, P., Wienisch, M., Zhang, Q., Colvin, S. M., & Feng, G. (2021) · Cell · doi:10.1016/j.cell.2021.04.035 · Cited by 102
Boutin, J., Rosier, J., Cappellen, D., Prat, F., Toutain, J., Pennamen, P., Bouron, J., Rooryck, C., Merlio, J., Lamrissi‐Garcia, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25190-6 · Cited by 90
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 85
Development and application of CRISPR/Cas9 technologies in genomic editing
Zhang, C., Quan, R., & Wang, J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy120 · Cited by 86
Nelson, J. P., Selin, C. L., & Scott, C. T. (2021) · Journal of Responsible Innovation · doi:10.1080/23299460.2021.1957579 · Cited by 90
Schimmel, J., Muñoz-Subirana, N., Kool, H., van Schendel, R., van der Vlies, S., Kamp, J. A., de Vrij, F. M. S., Kushner, S. A., Smith, G. C. M., Boulton, S. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112019 · Cited by 74
Recent advances in CRISPR/Cas9-mediated knock-ins in mammalian cells
Banan, M. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.11.010 · Cited by 85
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Strategies for Efficient Genome Editing Using CRISPR-Cas9
Farboud, B., Severson, A. F., & Meyer, B. J. (2018) · Genetics · doi:10.1534/genetics.118.301775 · Cited by 71
Kaya, K. D., Chen, H. Y., Brooks, M. J., Kelley, R. A., Shimada, H., Nagashima, K., de Val, N., Drinnan, C. T., Gieser, L. M., Kruczek, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/733071 · Cited by 88
“Despite studies using human preimplantation embryos [3,4] and fetal tissue [5-7], the complexities of human organogenesis are poorly understood [8,9].”
BackgroundBasic and Clinical Approaches for Fertility Preservation and Restoration in Cancer Patients
Medrano, J. V., Andrés, M. D. M., García, S., Herraiz, S., Vilanova-Pérez, T., Goossens, E., & Pellicer, A. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.10.010 · Cited by 75
Principles of and strategies for germline gene therapy
Wolf, D. P., Mitalipov, P. A., & Mitalipov, S. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0473-8 · Cited by 82
Self-citationNovel Therapies for Prevention and Early Treatment of Cardiomyopathies: Now and in the Future
Repetti, G. G., Toepfer, C. N., Seidman, J. G., & Seidman, C. E. (2019) · Circulation Research · doi:10.1161/circresaha.119.313569 · Cited by 78
“A proof-of-concept study aimed to perform prezygotic correction by ex vivo DNA manipulation of sperm that carried a 4-base pair pathogenic MYPBC3 deletion and an egg with a normal MYPBC3 allele.(15) This approach used CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspace…”
MethodPrediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment
Kang, S.-H., Lee, W.-J., An, J.-H., Lee, J., Kim, Y.-H., Kim, H., Oh, Y., Park, Y., Jin, Y. B., Jun, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17418-8 · Cited by 77
Self-citationMoral reasons to edit the human genome: picking up from the Nuffield report
Gyngell, C., Bowman-Smart, H., & Savulescu, J. (2019) · Journal of Medical Ethics · doi:10.1136/medethics-2018-105084 · Cited by 70
Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies
Brodehl, A., Ebbinghaus, H., Deutsch, M.-A., Gummert, J. F., Gärtner, A., Ratnavadivel, S., & Milting, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184381 · Cited by 78
Human Germline Genome Editing: On the Nature of Our Reasons to Genome Edit
Sparrow, R. (2022) · The American Journal of Bioethics · doi:10.1080/15265161.2021.1907480 · Cited by 40
Safe CRISPR: Challenges and Possible Solutions
Pineda, M., Lear, A., Collins, J. P., & Kiani, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.010 · Cited by 69
CRISPR/Cas9 gene-editing strategies in cardiovascular cells
Vermersch, E., Jouve, C., & Hulot, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz250 · Cited by 79
Preimplantation genetic testing: current challenges and future prospects
Kuliev, A., & Rechitsky, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1394186 · Cited by 72
“However, based on the recent progress in gene editing technologies [37], it may be postulated a possibility of CRISPRbased editing of the affected HLA matched embryos in the future, for those older patients who may no longer be able to produce a sufficient number of oocytes for a repeated cycle.”
BackgroundGene therapy strategies in the treatment of hypertrophic cardiomyopathy
Prondzynski, M., Mearini, G., & Carrier, L. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2173-5 · Cited by 74
De Wert, G., Heindryckx, B., Pennings, G., Clarke, A., Eichenlaub-Ritter, U., van El, C. G., Forzano, F., Goddijn, M., Howard, H. C., Radojkovic, D., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-017-0077-z · Cited by 68
“In a recent breakthrough article that appeared after the round of discussion in the professional Societies as discussed in the Introduction of this document, the group of Mitalipov (Ma et al., 2017) described the correction of a heterozygous mutation present in sperm by highly efficient genomic editing using CRISPR/Ca…”
BackgroundMethodInfluentialSmall molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells
Ma, X., Chen, X., Jin, Y., Ge, W., Wang, W., Kong, L., Ji, J., Guo, X., Huang, J., Feng, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03760-5 · Cited by 68
Innovative breeding technologies in lettuce for improved post-harvest quality
Damerum, A., Chapman, M. A., & Taylor, G. (2020) · Postharvest Biology and Technology · doi:10.1016/j.postharvbio.2020.111266 · Cited by 99
CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms
Brunner, E., Yagi, R., Debrunner, M., Beck-Schneider, D., Burger, A., Escher, E., Mosimann, C., Hausmann, G., & Basler, K. (2019) · Life Science Alliance · doi:10.26508/lsa.201800267 · Cited by 68
CRISPR Gene Editing in the Kidney
Cruz, N. M., & Freedman, B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.02.347 · Cited by 71
“A recent study describing correction of a mutation that causes hypertrophic cardiomyopathy in human embryos suggested higher efficiency with no evidence of off-target effects or mosaicism.(10) This was attributed to the double strand”
Osmond, A. T. Y., & Colombo, S. M. (2019) · Journal of the World Aquaculture Society · doi:10.1111/jwas.12595 · Cited by 131
Thoughts on the popularity of ICSI
Haddad, M., Stewart, J., Xie, P., Cheung, S. K., Trout, A., Keating, D., Parrella, A., Lawrence, S., Rosenwaks, Z., & Palermo, G. D. (2020) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-01987-0 · Cited by 87
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
Bloomer, H., Khirallah, J., Li, Y., & Xu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114087 · Cited by 78
Self-citationSimkin, D., Papakis, V., Bustos, B. I., Ambrosi, C. M., Ryan, S. J., Baru, V., Williams, L. A., Dempsey, G. T., McManus, O. B., Landers, J. E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.02.008 · Cited by 66
“, 2018) and human embryos (Alanis-Lobato et al., 2021; Liang et al., 2020;Ma et al., 2017; Zuccaro et al., 2020) and have also been shown to occur in human iPSCs (Blondal et al.”
BackgroundLi, Z., Wang, J., Xu, J.-P., Wang, J., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 93
Exploiting Bacteriophage Proteomes: The Hidden Biotechnological Potential
Santos, S. R. B., Costa, A. R., Carvalho, C. M., Nóbrega, F. L., & Azeredo, J. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.04.006 · Cited by 74
Genetics of Alzheimer's Disease
Kim, J. H. (2018) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2018.17.4.131 · Cited by 66
Self-citationA new possibility in fertility preservation: The artificial ovary
Cho, E., Kim, Y. Y., Noh, K., & Ku, S. (2019) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2870 · Cited by 76
O’Leary, T. S., Snyder, J. P., Sadayappan, S., Day, S. M., & Previs, M. J. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.12.003 · Cited by 69
Xenotransplantation: back to the future?
Meier, R. P. H., Müller, Y. D., Balaphas, A., Morel, P., Pascual, M. A., Seebach, J. D., & Bühler, L. H. (2018) · Transplant International · doi:10.1111/tri.13104 · Cited by 80
“Pigs lacking all three major carbohydrate xenoantigens, that is, GalT/CMAH/b4GalNT2 triple gene KO, were recently produced using the CRISPR/Cas9 technology [90].”
InfluentialCRISPR-Cas9 system: A genome-editing tool with endless possibilities
Tyagi, S., Kumar, R., Das, A., Won, S. Y., & Shukla, P. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.05.008 · Cited by 78
CRISPR gene editing in human embryos wreaks chromosomal mayhem
Ledford, H. K. (2020) · Nature · doi:10.1038/d41586-020-01906-4 · Cited by 74
Translation of New and Emerging Therapies for Genetic Cardiomyopathies
Helms, A. S., Thompson, A. D., & Day, S. M. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.012 · Cited by 72
“Another example would be patients with biallelic variants in genes that cause complete loss of function, such as MYBPC3.”
BackgroundInfluentialEfficient generation of Knock-in/Knock-out marmoset embryo via CRISPR/Cas9 gene editing
Kumita, W., Sato, K., Suzuki, Y., Kurotaki, Y., Harada, T., Zhou, Y., Kishi, N., Sato, K., Aiba, A., Sakakibara, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49110-3 · Cited by 67
Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement
Greene, M., & Master, Z. (2018) · Journal of Bioethical Inquiry · doi:10.1007/s11673-018-9865-6 · Cited by 67
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 69
“72 The authors hypothesized that the maternal allele was exchanged through IHR.”
Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice
Rashnonejad, A., Chermahini, G. A., Gündüz, C., Önay, H., Aykut, A., Durmaz, B., Baka, M., Su, Q., Gao, G., & Özkınay, F. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.017 · Cited by 65
Lea, R. A., & Niakan, K. K. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0424-0 · Cited by 69
Cheng, H., Shang, D., & Zhou, R. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01197-3 · Cited by 79
“Genome editing has been used to correct gene mutations in mice and mimic human genetic diseases, and correct pathogenic gene mutations in human embryos.(534,535) CRISPR-edited T cells in patients with cancers have been tested in clinical trials.”
BackgroundCreating cell and animal models of human disease by genome editing using CRISPR/Cas9
Zarei, A., Razban, V., Hosseini, S. E., & Tabei, K. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3082 · Cited by 74
“By applying the aforementioned changes in genome editing, researchers were able to modify the heterozygous MYBPC3 mutations in human pre‐implantation embryos with maximum efficiency.(99)”
MethodMa, S., Smagghe, G. J., & Xia, Q. (2018) · Insect Science · doi:10.1111/1744-7917.12609 · Cited by 70
“Ma et al. (2017b) introduced SaCas9 and AsCpf1, in which PAM sites are NNGRRT and TTTN, respectively.”
BackgroundInfluentialYesterday’s Child: How Gene Editing for Enhancement Will Produce Obsolescence—and Why It Matters
Sparrow, R. (2019) · The American Journal of Bioethics · doi:10.1080/15265161.2019.1618943 · Cited by 68
“…note that there remains some controversy about the extent to which CRISPR/Cas9 generates “ off-target effects ” (Knoepfler 2017; Liang et al. 2015; Ma et al. 2017; Scott and Zhang 2017), as well as the significance of such effects for the ethics of the use of the technology (compare, for…”
Molecular mechanisms of psychiatric diseases
Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 69
“(188) corrected the heterozygous MYBPC3 mutation”
Carvalho, M. A. B. R., Sepodes, B. M. N., & Martins, A. P. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00182 · Cited by 75
“Finally, there was no evidence of off-target mutations (105).”
BackgroundRanisch, R. (2020) · Bioethics · doi:10.1111/bioe.12635 · Cited by 48
CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities
Roy, B., Zhao, J. C., Yang, C., Luo, W., Xiong, T., Li, Y., Fang, X., Gao, G., Singh, C. O., Madsen, L., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00240 · Cited by 67
“However, the successful correction of a gene in 42 out of 58 human embryos was recently reported (Ma et al., 2017).”
BackgroundSelf-citationDewari, P. S., Southgate, B., McCarten, K., Monogarov, G., O’Duibhir, E., Quinn, N., Tyrer, A., Leitner, M.-C., Plumb, C., Kalantzaki, M., et al. (2018) · eLife · doi:10.7554/elife.35069 · Cited by 64
Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy
Grosch, M., Schraft, L., Chan, A., Küchenhoff, L., Rapti, K., Ferreira, A.-M., Kornienko, J., Li, S., Radke, M. H., Krämer, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39352-1 · Cited by 64
Motta, B. M., Pramstaller, P. P., Hicks, A. A., & Rossini, A. (2017) · Stem Cells International · doi:10.1155/2017/8960236 · Cited by 68
“used the CRISPR/Cas9 system to correct a heterozygous mutation in the MYBPC3 gene, which can lead to hypertrophic cardiomyopathy, in human embryos specifically created with the sperm of a donor carrying the mutation [168].”
MethodRose, J. C., Popp, N. A., Richardson, C. D., Stephany, J. J., Mathieu, J., Wei, C. T., Corn, J. E., Maly, D. J., & Fowler, D. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16542-9 · Cited by 58
Risks and benefits of human germline genome editing: An ethical analysis
Rubeis, G., & Steger, F. (2018) · Asian Bioethics Review · doi:10.1007/s41649-018-0056-x · Cited by 49
Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique
Marangi, M., & Pistritto, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00396 · Cited by 66
“Similar approach in human embryos was also used for the correction of heritable MYBPC3 mutation implicated in hypertrophic cardiomyopathy (Ma et al., 2017).”
Tachibana, M., Kuno, T., & Yaegashi, N. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12230 · Cited by 59
Evans, J. H. (2020) · doi:10.1093/oso/9780197519561.001.0001 · Cited by 63
Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 93
Tadros, H. J. J., Life, C. S., García, G., Pirozzi, E. J., Jones, E. G., Datta, S., Parvatiyar, M. S., Chase, P. B., Allen, H. D., Kim, J. J., et al. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.04.005 · Cited by 55
“For example, CRISPR-Cas9 targeting of a GAGT deletion in MYBPC3 in human embryos and expression of functional cMYBPC in MYBPC3 knockout mice with use of AAV therapy [23, 24].”
Self-citationLeft Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Sayın, B. Y., & Oto, A. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00260-y · Cited by 67
“Germline editing is attractive for the treatment of monogenic diseases, as progeny of the treated embryo could prevent transmission of mutations to future generations [93, 94].”
BackgroundGeneration of knock-in cynomolgus monkey via CRISPR/Cas9 editing
Yao, X., Liu, Z., Wang, X., Wang, Y., Nie, Y., Lai, L. C., Sun, R., Shi, L., Sun, Q., & Yang, H. (2018) · Cell Research · doi:10.1038/cr.2018.9 · Cited by 61
Therapeutic applications of CRISPR/Cas9 system in gene therapy
Mollanoori, H., & Teimourian, S. (2018) · Biotechnology Letters · doi:10.1007/s10529-018-2555-y · Cited by 62
Charlier, J., Nadon, R., & Makarenkov, V. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab112 · Cited by 63
Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics
Keyt, L. K., Duran, J. M., Bui, Q. M., Chen, C., Miyamoto, M. I., Enciso, J. S., Tardiff, J. C., & ADLER, E. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.972301 · Cited by 52
Aburass, S., Dorgham, O. M., & Shaqsi, J. A. (2024) · Systems and Soft Computing · doi:10.1016/j.sasc.2024.200110 · Cited by 85
New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells
Daga, S., Donati, F., Capitani, K., Croci, S., Tita, R., Giliberti, A., Valentino, F., Benetti, E., Fallerini, C., Niccheri, F., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0537-8 · Cited by 60
CRISPR technology: The engine that drives cancer therapy
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z.-B., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111007 · Cited by 55
CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing
Hossain, M. A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.001 · Cited by 68
Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Xu, M., Zhang, K., & Song, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623674 · Cited by 61
Genetic Testing in Patients with Hypertrophic Cardiomyopathy
Bonaventura, J., Polaková, E., Vejtasová, V., & Veselka, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910401 · Cited by 59
“The correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response was recently reported [96].”
BackgroundAlam, Z., Shang, X., Effat, K., Kanwal, F., He, X., Li, Y., Xu, C., Niu, W., War, A. R., & Zhang, Y. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14302 · Cited by 62
Self-citationMonkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease
Tsukiyama, T., KOBAYASHI, K. P., Nakaya, M., Iwatani, C., Seita, Y., Tsuchiya, H., Matsushita, J., Kitajima, K., Kawamoto, I., Nakagawa, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13398-6 · Cited by 57
Ethical issues related to research on genome editing in human embryos
Niemiec, E., & Howard, H. C. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.014 · Cited by 64
“Within the studies on human GGE listed in Table 1, five experiments involved egg donation: in one study, oocytes were procured specifically for research [30], in the remaining studies, immature oocytes obtained in clinical IVF procedures were used [31,32,35,61].”
BackgroundTurocy, J. M., Adashi, E. Y., & Egli, D. M. (2021) · Cell · doi:10.1016/j.cell.2021.02.036 · Cited by 61
CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo
Aryal, N. K., Wasylishen, A. R., & Lozano, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1146-0 · Cited by 61
Zaleta-Rivera, K., Dainis, A., Ribeiro, A. J. S., Cordero, P., Rubio, G. R., Shang, C., Liu, J., Finsterbach, T., Parikh, V. N., Sutton, S. C., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036965 · Cited by 49
CRISPR–Cas9 in genome editing: Its function and medical applications
Khadempar, S., Familghadakchi, S., Motlagh, R. A., Farahani, N., Dashtiahangar, M., Rezaei, H., & Gheibi Hayat, S. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27476 · Cited by 49
Park, J. E., & Silva, A. C. (2019) · American Journal of Primatology · doi:10.1002/ajp.22931 · Cited by 49
Therapeutic Genome Editing in Cardiovascular Diseases
German, D. M., Mitalipov, S. M., Mishra, A., & Kaul, S. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.004 · Cited by 61
“(6), might further improve these results.”
BackgroundInfluentialSelf-citationCRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment
Bonowicz, K., Jerka, D., Piekarska, K., Olagbaju, J., Stapleton, L., Shobowale, M., Bartosiński, A., Łapot, M., Bai, Y., & Gagat, M. (2025) · Cells · doi:10.3390/cells14020131 · Cited by 64
“This early intervention demonstrates the promise of correcting inherited mutations at the zygotic stage, potentially preventing the onset of disease before birth [29].”
Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction.
Cribbs, A. P., & Perera, S. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 95
Outlook and future of inner ear therapy
Devare, J., Gubbels, S. P., & Raphael, Y. (2018) · Hearing Research · doi:10.1016/j.heares.2018.05.009 · Cited by 51
“…one emerging area of research involves using the CRISPR-Cas gene editing system to modify gene mutations (Gao et al., 2018; Liang et al., 2015; Ma et al., 2017); however, there are still challenges to overcome to ensure that the correct gene is reliably altered without producing off-target…”
The Clinical Application of Gene Editing: Ethical and Social Issues
Ormond, K. E., Bombard, Y., Bonham, V. L., Hoffman‐Andrews, L., Howard, H. C., Isasi, R. M., Musunuru, K., Riggan, K. A., Michie, M., & Allyse, M. A. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0155 · Cited by 59
Gene-edited babies: What went wrong and what could go wrong
Wang, H., & Yang, H. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000224 · Cited by 57
“Work done by the Mitalipov’s group suggests that the maternal allele could serve as a template for gene repair to achieve correction of pathogenic mutation [12], but other groups have argued that Cas9 may induce large-scale deletions or rearrangements that lead to false positive results using PCR-based genotyping [14].”
BackgroundResultKyrochristos, I. D., & Roukos, D. H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101894 · Cited by 54
“Therefore, the revolutionary capacity for precision editing both ex-vivo and in-vivo has delivered a transformative tool in the discovery of novel oncotargets and drugs in pre-clinical studies, while the first early-phase clinical trials on various diseases, including leukemias and solid tumors, implementing genome ed…”
BackgroundCould Failure in Preimplantation Genetic Diagnosis Justify Editing the Human Embryo Genome?
Steffann, J., Jouannet, P., Bonnefont, J.-P., Chneiweiss, H., & Frydman, N. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.01.004 · Cited by 47
Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG
Ma, S., Jiang, W., Liu, X., Lu, W., Qi, T., Wei, J., Wu, F., Chang, Y., Zhang, S., Song, Y., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318674 · Cited by 47
CRISPR in Animals and Animal Models
Shrock, E., & Güell, M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 45
Compelling Reasons for Repairing Human Germlines
Church, G. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1710370 · Cited by 37
CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
Lone, B. A., Karna, S. K. L., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2018) · Genetics Research International · doi:10.1155/2018/3797214 · Cited by 60
“This technology has been used to edit the mutations in human embryos causing β-thalassemia [146] and hypertrophic-cardiomyopathy [147].”
MethodWang, X., Dong, K., Kong, D., Zhou, Y., Yin, J., Cai, F., Wang, M., & Ye, H. (2021) · Science Advances · doi:10.1126/sciadv.abh2358 · Cited by 51
Unexpected CRISPR on-target effects
Lee, H., & Kim, J.-S. (2018) · Nature Biotechnology · doi:10.1038/nbt.4207 · Cited by 46
Self-citationTransfection by cationic gemini lipids and surfactants
Damen, M., Groenen, A., van Dongen, S. F. M., Nolte, R. J. M., Scholte, B. J., & Feiters, M. C. (2018) · MedChemComm · doi:10.1039/c8md00249e · Cited by 49
Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing
Zhang, X., Li, T., Ou, J., Huang, J., & Liang, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00838-7 · Cited by 52
Fast but not furious: a streamlined selection method for genome-edited cells
Ramachandran, H., Martins, S., Kontarakis, Z., Krutmann, J., & Rossi, A. (2021) · Life Science Alliance · doi:10.26508/lsa.202101051 · Cited by 46
“It was shown to be potentially useful clinically in correcting genetic DNA mutations and to treat diseases that are refractory to traditional therapies or where therapies are not available yet (Pires et al, 2016; Ma et al, 2017; Min et al, 2019).”
BackgroundThe ethics of clinical applications of germline genome modification: a systematic review of reasons
van Dijke, I., Bosch, L., Bredenoord, A. L., Cornel, M. C., Repping, S., & Hendriks, S. (2018) · Human Reproduction · doi:10.1093/humrep/dey257 · Cited by 53
“, 2017), remarkable progress has been reported, including high on-target specificity without off-target effects; although half of the embryos still had the mutation and more studies are needed to ensure reproducibility and safety (Ma et al., 2017).”
Background
Metadata
- Authors
- Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A.-R., Kim, D., Kim, S.-T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J.-S., Kaul, S., & Mitalipov, S.
- Affiliations
- Oregon Health & Science University (US)
- Institute for Basic Science (KR)
- Salk Institute for Biological Studies (US)
- Seoul National University (KR)
- BGI Group (China) (CN)
- Corresponding author
- Amato, Paula
- Kim, Jin-Soo
- Kaul, Sanjiv
- Mitalipov, Shoukhrat
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7668
- Pages
- 413-419
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2740810575
- Cited by
- 992
- References
- 48
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 47 · 2023: 93 · 2022: 75 · 2021: 107 · 2020: 135 · 2019: 155 · 2018: 217 · 2017: 88
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2017-10-02)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Oregon Health and Science University
- Leona M. and Harry B. Helmsley Charitable Trust
- Consorzio Interuniversitario Biotecnologie
- Moxie Foundation
- Government of Jiangxi Province
- Institute for Basic Science (IBSR021-D1, R021-D1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- germline editing, CRISPR/Cas9, MYBPC3 mutation, hypertrophic cardiomyopathy, preimplantation embryo, homology-directed repair, mosaicism, DNA double-strand break repair, cell cycle timing, preimplantation genetic diagnosis, off-target mutations
- MeSH terms
- Gene Editing, Myosin Binding Protein C, Adult, Alleles, Blastocyst, Carrier Proteins, Cell Division, Embryo, Mammalian, Genetic Complementation Test, Heterozygote, Homozygote, Humans, Male, Mosaicism, Mutation, Templates, Genetic, Zygote, S Phase, Gene Targeting, DNA Breaks, Double-Stranded, Recombinational DNA Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.